THRX: Summary for Theravance, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 10:45am EST - Canadian Markets close in 5 hours and 15 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Theravance Inc. (THRX)

At 10:30 EST: 13.46 USD

0.06 (0.45%)

MORE ON THRX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Theravance, Inc. (NGM:THRX) Delayed quote data

Last Trade:	13.46 USD
Trade Time:	10:30AM EST
Change:	0.06 (0.45%)
Prev Close:	13.40
Open:	13.81
Bid:	13.45 x 800
Ask:	13.49 x 200
1y Target Est:	31.00

Day's Range:	13.42 - 13.54
52wk Range:	5.77 - 18.56
Volume:	69,069
Avg Vol (3m):	328,365
Market Cap:	855.54M
P/E (ttm):	N/A
EPS (ttm):	-2.73
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add THRX to Portfolio

Download Data

HEADLINES

•	Unique Strategy Generates Big Returns for Baupost
	Indie Research (Fri, Nov 13)

•	THERAVANCE INC Financials
	EDGAR Online Financials (Tue, Nov 10)

•	Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
	Marketwire (Thu, Nov 5)

•	THERAVANCE INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Wed, Nov 4)

•	Theravance to Present at the 18th Annual Credit Suisse Health Care Conference
	Marketwire (Tue, Nov 3)

•	Theravance Announces New Employment Inducement Award
	Marketwire (Mon, Nov 2)

•	Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe
	Marketwire (Wed, Oct 28)

•	THRX's Loss Wider Than Expected
	Zacks.com (Wed, Oct 28)

•	Theravance, Inc. Q3 2009 Earnings Call Transcript
	at Seeking Alpha (Tue, Oct 27)

•	Theravance Third Quarter 2009 Financial Results Call scheduled for 5:00 pm ET today
	Shareholder.com (Tue, Oct 27)

•	THERAVANCE INC Files SEC form 8-K, Results of Operations and Financial Condition
	EDGAR Online (Tue, Oct 27)

More Headlines for THRX...

ANALYST

EPS Est (next year) (Dec-07) :	-2.64
EPS Est (in 2 years) (Dec-08) :	-1.88
Avg Rec (current)*:	2.1
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•